Cormedix Inc is a biopharmaceutical company focused on developing innovative therapies aimed at improving the lives of patients with serious medical conditions
The company primarily concentrates on treatments for infections related to catheter use and other healthcare-associated infections. Cormedix is dedicated to advancing its proprietary product candidates through clinical trials and regulatory pathways, with an emphasis on addressing unmet medical needs in the fields of nephrology and infectious diseases. Through its research and development efforts, Cormedix aims to provide effective and safe therapeutic solutions that enhance patient outcomes.
San Diego, CA -- (SBWIRE) -- 09/21/2022 -- An update was announced in the lawsuit that is pending for certain investors in shares of CorMedix Inc. (NASDAQCRMD).
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CorMedix, Inc. (NASDAQCRMD) on behalf of long-term stockholders following a class action complaint that was filed against CorMedix on July 22, 2021 with a Class Period from July 8, 2020 to May 13, 2021. Our investigation concerns whether the board of directors of CorMedix have breached their fiduciary duties to the company.
San Diego, CA -- (SBWIRE) -- 10/21/2021 -- Certain directors of CorMedix Inc. are under investigation concerning potential breaches of fiduciary duties.
NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't
NEW YORK, NY / ACCESSWIRE / September 20, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you. CorMedix Inc. (NASDAQCRMD)If you suffered a loss, contact us at:
NEW YORK, NY / ACCESSWIRE / September 20, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. Coinbase Global, Inc. (NASDAQCOIN) This lawsuit is on behalf of all persons and entities that
NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you. CRMD Shareholders Click Here:
NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. CorMedix Inc. (NASDAQCRMD) Class Period: October 16, 2019 - May 13, 2021 Lead Plaintiff Deadline:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQCRMD) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired CorMedix securities between October 16, 2019 and May 13, 2021, both dates inclusive (the “Class Period”). Investors have until September 20, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any
NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you. CorMedix Inc. (NASDAQCRMD) If you suffered a loss, contact us at:
NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. CorMedix Inc. (NASDAQCRMD) Class Period: October 16, 2019 - May 13, 2021 Lead Plaintiff Deadline:
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or "the Company") (NASDAQCRMD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired CorMedix securities between July 8, 2020 and May 13, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/crmd.
NEW YORK, NY / ACCESSWIRE / September 17, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you. CRMD Shareholders Click Here:
SAN DIEGO, CA / ACCESSWIRE / September 16, 2021 / Robbins Geller Rudman & Dowd LLP announces that purchasers of CorMedix Inc. (NASDAQCRMD) securities between October 16, 2019 and May 13, 2021, inclusive ("Class Period") have until this upcoming Monday, September 20, 2021, to seek appointment as lead plaintiff. The CorMedix class action lawsuit charges CorMedix and certain of its top executives with violations of the Securities Exchange Act
SAN DIEGO, CA / ACCESSWIRE / September 16, 2021 / Robbins Geller Rudman & Dowd LLP announces that purchasers of CorMedix Inc. (NASDAQCRMD) securities between October 16, 2019 and May 13, 2021, inclusive ("Class Period") have until this upcoming Monday, September 20, 2021, to lead the CorMedix class action lawsuit. The CorMedix class action lawsuit charges CorMedix and certain of its top executives with violations of the Securities Exchange
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CorMedix Inc. (“CorMedix” or “the Company”) (NASDAQCRMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CorMedix Inc. (“CorMedix” or “the Company”) (NASDAQCRMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Robbins Geller Rudman & Dowd LLP announces that purchasers of CorMedix Inc. (NASDAQCRMD) securities between October 16, 2019 and May 13, 2021, inclusive (“Class Period”) have until this upcoming Monday, September 20, 2021, to seek appointment as lead plaintiff in the CorMedix class action lawsuit. The CorMedix class action lawsuit charges CorMedix and certain of its top executives with violations of the Securities Exchange Act of 1934. The first-filed CorMedix class action lawsuit (Patrick v. CorMedix Inc., No. 21-cv-14020) is pending in the District of New Jersey.
NEW YORK, NY / ACCESSWIRE / September 14, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a Lead Plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of CorMedix Inc. ("CorMedix" or the "Company") (NASDAQCRMD) from July 8, 2020 through May 13, 2021 (the "Class Period"). The lawsuit filed in
NEW YORK, NY / ACCESSWIRE / September 14, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you. CRMD Shareholders Click Here:
